Amakuru
Uburyo bushya bwo kuvura ingirabuzima fatizo bwageze ku ntambwe ishimishije mu kuvura indwara ya Sickle Cell na Thalassemia
Mu rubanza rw’ibanze rw’ubuvuzi, umurwayi w’imyaka 21 yatsinze neza ibibazo bya thalassemia binyuze mu buvuzi bugezweho bushingiye kuri CRISPR bushingiye ku ngirabuzima fatizo. Ubu buryo bushya bugaragaza intambwe ikomeye mu kuvura indwara zikomeye z’amaraso nka sickle cell disease (SCD) na thalassemia.
ASH 2024: Itsinda rya Lu Daopei ryerekanye ibyagezweho mu bushakashatsi 13 mu bijyanye n'amaraso
Mu nama iteganyijwe ya ASH 2024, itsinda ry’abaganga bo mu bitaro bya Lu Daopei rizagaragaza ibyavuye mu bushakashatsi 13 bw’ingenzi, bigaragaza iterambere mu bijyanye n’amaraso n’ubushobozi bwo kuvura CAR-T, bongera kwemeza ko bashyizeho umwete mu kunoza umusaruro w’abarwayi.
Kurwanya Lymphoma hakoreshejwe uburyo bubiri bwo kuvura CAR-T
Nyuma yo kumara imyaka itatu arwaye kanseri y’urubogobogo, umugore w’imyaka 61 yakize burundu binyuze mu buvuzi bushya bwa CAR-T muri BIOOCUS, agaragaza ubushobozi bwo kuvura kanseri mu buryo buhanitse.
Guhindura Impinduka mu Guhindura Ingirabuzimafatizo: Iterambere mu Ikoranabuhanga rya CRISPR/Cas mu Ikoreshwa rya Biomedical
Iterambere riherutse mu ikoranabuhanga rya CRISPR/Cas ririmo guhindura imiterere y’ubushakashatsi ku ngirabuzimafatizo mu bushakashatsi ku buvuzi bw’ibinyabuzima. Iyi nkuru irasuzuma ikoreshwa ryayo, igaragaza ubushobozi bunini bwo kuvura indwara z’ngirabuzimafatizo, kanseri, n’indwara zandura.
Ubukode bushya ku buzima: Uburyo bwiza bwo kuvura CD7 CAR-T bufasha umwana w'imyaka 15 gutera T-ALL yasubitse
Urugero rutangaje muri BIOOCUS rwerekana ingaruka nziza zo kuvura CD7 CAR-T ku mwana w’imyaka 15 wari ufite kanseri y’amaraso ya T-cell acute lymphoblastic leukemia (T-ALL) yongeye kugaragara, bigatuma akira burundu kandi agaterwa ubwa kabiri neza.
Bioocus yitabiriye IGC 2024 kugira ngo ishakishe ubufatanye bushya n'uburyo bushya bw'ubucuruzi mu buvuzi bw'imyororokere n'uturemangingo
Bioocus yishimiye kwinjira mu nama ya 8 y’ubuvuzi bw’uturemangingo n’uturemangingo (IGC 2024)! Twiteguye gukorana n’inzobere ku isi no gushakisha uburyo bushya bw’ubucuruzi bujyanye n’ikoranabuhanga rigezweho ryo kuvura uturemangingo n’uturemangingo. Twese hamwe, reka dushyireho ejo hazaza ho kuvura ubudahangarwa bw’umubiri.
Gucunga ingaruka mbi zo kuvura uturemangingo twa CAR-T: Ibisobanuro by'ingenzi byavuye mu bushakashatsi buherutse gukorwa
Iyi nkuru y’amakuru igaragaza ubushakashatsi buherutse gukorwa ku kuvura uburozi bwa CAR-T cell therapy kuri lymphomas za B-cell. Ubu bushakashatsi bushimangira ingamba zo guhangana n’ingaruka zisanzwe nka cytokine release syndrome (CRS) na neurotoxicity (ICANS), hagamijwe ko ubu buryo bw’ubuvuzi bukoreshwa neza.
Ingufu nyinshi zo kuvura CD7 CAR-T ku ndwara za B-cell: Iterambere mu kuvura kanseri
Ubushakashatsi buheruka bwerekana akamaro n'umutekano wa CD7 CAR-T selile mu kuvura kanseri y'amaraso ya B-cell acute lymphoblastic leukemia (B-ALL) yasubiwemo cyangwa itarakira na T-cell lymphoblastic lymphoma (T-LBL). Ubu bushakashatsi bwakozwe na BIOOCUS ku bufatanye n'ibitaro bya Lu Daopei, bugaragaza umusaruro mwiza ku barwayi, butanga ubundi buryo bukomeye bwo kuvura kanseri busanzwe.
Icyizere Gishya ku Buvuzi bwa Chimiotherapie-Refractory B-Cell Lymphoma: Ubuvuzi bwa CAR-T bwagaragaje umusaruro mwiza
Ubushakashatsi, bwasohotse mu kinyamakuru Ikinyamakuru cy'ubuvuzi bwa kanseri, igaragaza igipimo gikomeye cyo koroherwa ku barwayi bari barakoresheje uburyo bwa gakondo bwo kuvura, bikaba bigaragaza iterambere ryiza mu kuvura kanseri.
Ingaruka nziza zo kuvura CD7 CAR-T hamwe no gutera ubwa kabiri ku barwayi ba T-ALL/LBL basubijwe mu buzima bwabo
Ubushakashatsi buherutse gukorwa bwerekana akamaro k’ubuvuzi bwa CD7 CAR-T bugakurikirwa n’uburyo bwa kabiri bwo guteranya uturemangingo tw’amaraso mu maraso (HSCT) ku barwayi ba T-cell acute lymphoblastic leukemia (T-ALL) na lymphoblastic lymphoma (LBL) byasubiwemo, bigaragaza ubushobozi bukomeye bwo kugera ku buremere bw’indwara ntoya zisigaye (MRD)-negative.
Ingufu z'igihe kirekire zo kuvura CD19 CAR T-cells mu kuvura Leukemia yo mu bwoko bwa Acute Lymphoblastic Leukemia yasubiwemo/yasubiwemo
Ubushakashatsi bw’ingenzi bwagaragaje ko uburyo CD19 CAR T-selile zavuwe bwagize icyo bugeraho mu kuvura abarwayi bafite leukemia ya lymphoblastic yasubiwemo/yasubiwemo nyuma yo gutera uturemangingo tw’amaraso twa allogeneic hematopoietic, butanga icyizere gishya mu bijyanye n’amaraso.
Bioocus Yateye Imbere Umupaka Mu Kuvura Abana Barwaye Leukemia Ikabije ya Lymphoblastic
Bioocus iri ku isonga mu guteza imbere uburyo bwo kuvura kanseri bw’ikigero gishya. Inyandiko iherutse gusohoka yanditswe na Dr. Chunrong Tong n’ikipe ye mu bitaro bya Lu Daopei igaragaza iterambere rikomeye n’imbogamizi mu ikoreshwa ry’uburyo bwo kuvura kanseri bw’ikigero cya kabiri bwa CD19 ku barwayi b’abana, igaragaza ubwitange bwa Bioocus mu kuvura kanseri mu buryo bushya.